111 Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

111 Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,166	Closed	-$115K	–	453
2025 Q2	$115K	Buy	+14,166	New	+$107K	0.02%	475

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

111 Capital's AMRX Position: Q3 2025 in Review

111 Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 14,166 shares — an estimated $115K sold.

111 Capital first reported a position in AMRX in Q2 2025 and held it in 1 quarter. The position peaked at $115K in Q2 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

111 Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
111 Capital sold 14,166 Amneal Pharmaceuticals shares in Q3 2025, an estimated $115K.
111 Capital first reported a position in Amneal Pharmaceuticals in Q2 2025 and held it in 1 quarter.
111 Capital's Amneal Pharmaceuticals position peaked at $115K in Q2 2025.
248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.